SA030 / Suzhou Siran Biotechnology, GSK - LARVOL DELTA

GSK secures global rights (outside China, Hong Kong, Macau, Taiwan) to SiranBio’s SA030, a long-acting ALK7-targeting siRNA therapy, for up to $1bn, including upfront payment, milestone payments, and potential royalties (MSN News) - "SA030 aims to reduce abdominal fat, lower cardiometabolic risk, and preserve muscle mass, offering an alternative to GLP-1RAs and SGLT2 inhibitors for obesity and type 2 diabetes."

Licensing / partnership • Obesity • Type 2 Diabetes Mellitus

A Study of SA030 Injection in Overweight or Obese Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Suzhou Siran Biotechnology Co.,Ltd.

New P1 trial • Obesity